

COMMENTARY

- 121** **Marshaling the Translational Potential of *MC1R* for Precision Risk Assessment of Melanoma**
Peter A. Kanetsky and Jennifer L. Hay

EDITORIAL

- 125** **Targeting Epigenetics to Prevent Obesity Promoted Cancers**
Nathan A. Berger and Peter C. Scacheri
See related article, p. 129

RESEARCH ARTICLES

- 129** **A BET Bromodomain Inhibitor Suppresses Adiposity-Associated Malignant Transformation**
Debrup Chakraborty, Vanessa Benham, Vladislav Jdanov, Blair Bullard, Ana S. Leal, Karen T. Liby, and Jamie J. Bernard
See related editorial, p. 125

- 143** **Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762**

Di Zhang, Ana S. Leal, Sarah Carapellucci, Kayla Zydeck, Michael B. Sporn, and Karen T. Liby

- 157** **Effects of Black Raspberry on Dibenzo[*a,l*]Pyrene Diol Epoxide Induced DNA Adducts, Mutagenesis, and Tumorigenesis in the Mouse Oral Cavity**

Kun-Ming Chen, Joseph B. Guttenplan, Yuan-Wan Sun, Timothy Cooper, Nora A.E. Shalaby, Wieslawa Kosinska, Gabrielle Benitez, Cesar Aliaga, Junjia Zhu, Jason Liao, Krishne Gowda, Shantu Amin, Gary Stoner, and Karam El-Bayoumy


- 165** **Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years**

Michelle I. Silver, Julia C. Gage, Mark Schiffman, Barbara Fetterman, Nancy E. Poitras, Thomas Lorey, Li C. Cheung, Hormuzd A. Katki, Alexander Locke, Walter K. Kinney, and Philip E. Castle

ABOUT THE COVER

Epidemiological evidence implicates obesity and the deposition of excess visceral adipose tissue (VAT) in increasing the risk of different cancers, including breast cancer, and cancers of prostate, colon, and esophagus. Cancer is the second foremost cause of death globally, and obesity may contribute to 20% of all cancer-related deaths in the United States. As previously demonstrated by this group, fibroblast growth factor-2 (FGF2) released from VAT induced malignant transformation of non-tumorigenic epithelial cells. At present, there is no preventive measure available in the clinic to prevent VAT/obesity-induced malignant transformation and early-stage cancers.

However, Chakraborty and colleagues describe a possible therapeutic approach by administering a bromodomain inhibitor, I-BET 762 (beginning on page 129). The study demonstrated that VAT and FGF2 upregulate c-Myc protein expression and inhibition of c-Myc at the transcriptional level attenuates malignant transformation. I-BET 762 is currently in clinical trials for the treatment of cancers. Therefore, understanding the critical molecular mechanisms associated with I-BET 762-induced attenuation of transformation may offer a new therapeutic approach to prevent obesity-associated cancers. The cover immunofluorescent image shows overexpressed nuclear c-Myc (in red) in JB6 P+ mouse epidermal cells treated with VAT.



Cancer Prevention Research

11 (3)

Cancer Prev Res 2018;11:121-170.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/11/3>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/11/3>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.